ABCG2 and non-small cell lung carcinoma: We have shown that specific drug transporter expression is characteristic to NSCLC subtypes but cisplatin can change the characteristically non-canonical (Wnt5a) microenvironment of SCC by activating the beta-catenin dependent route leading to ABCB1 and ABCG2 up-regulation.